IGC Pharma, Inc. (IGC)
NYSEAMERICAN: IGC · Real-Time Price · USD
0.3191
-0.0003 (-0.09%)
Nov 28, 2025, 4:00 PM EST - Market closed
IGC Pharma Revenue
IGC Pharma had revenue of $191.00K in the quarter ending September 30, 2025, a decrease of -53.64%. This brings the company's revenue in the last twelve months to $1.11M, down -6.51% year-over-year. In the fiscal year ending March 31, 2025, IGC Pharma had annual revenue of $1.27M, down -5.50%.
Revenue (ttm)
$1.11M
Revenue Growth
-6.51%
P/S Ratio
23.88
Revenue / Employee
$15,800
Employees
70
Market Cap
29.63M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 1.27M | -74.00K | -5.50% |
| Mar 31, 2024 | 1.35M | 434.00K | 47.64% |
| Mar 31, 2023 | 911.00K | 514.00K | 129.47% |
| Mar 31, 2022 | 397.00K | -501.00K | -55.79% |
| Mar 31, 2021 | 898.00K | -3.17M | -77.95% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
IGC News
- 3 days ago - IGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Factors Driving Alzheimer's and Aging Trends - Accesswire
- 11 days ago - IGC Pharma Reports Accelerated Q2 Progress and Strengthened Financial Focus: CALMA Trial Passes 50% Enrollment Milestone, Strategic Divestiture Optimizes Capital - Accesswire
- 15 days ago - USPTO Grants IGC Pharma Patent Covering IGC-AD1 for Novel Composition Targeting Alzheimer's Disease and Central Nervous System Disorders - Accesswire
- 18 days ago - IGC Pharma to Host Mid-Year Fiscal 2026 Shareholder Update Call on November 17, 2025 - Accesswire
- 25 days ago - IGC Pharma Expands AI-Powered Drug Discovery In-Silico Pipeline - Accesswire
- 5 weeks ago - IGC Pharma Advances to Semi-Finals in the Alzheimer's Insights AI Prize with "AHA: Agentic Harmonization Assistant" - Accesswire
- 6 weeks ago - IGC Pharma Expands Phase 2 CALMA Clinical Trial to University of South Florida's Department of Psychiatry and Behavioral Neurosciences - Accesswire
- 6 weeks ago - IGC Pharma Announces Results of 2025 Annual Meeting of Stockholders - Accesswire